BioE PhD Proposal - Afsane Radmand

Event Details
  • Date/Time:
    • Monday October 3, 2022
      11:00 am - 1:00 pm
  • Location: https://gatech.zoom.us/j/93835347627?pwd=TjNaR0pGc1JUeEVra2tBcHZLNnJQQT09
  • Phone:
  • URL:
  • Email:
  • Fee(s):
    N/A
  • Extras:
Contact
No contact information submitted.
Summaries

Summary Sentence: "Next-generation lipid nanoparticle formulations for non-liver delivery of nucleic acid-based therapies and vaccines "

Full Summary: BioE PhD Proposal - "Next-generation lipid nanoparticle formulations for non-liver delivery of nucleic acid-based therapies and vaccines  " - Afsane Radmand

Advisor:  

James E. Dahlman, Ph.D. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University 

 

Committee Members: 

 

Philip J. Santangelo, Ph.D. 

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University 

 

Julie A. Champion, Ph.D. 

Department of Chemical and Biomolecular Engineering, Georgia Institute of Technology 

 

Wilber Lam, Ph.D.  

Department of Biomedical Engineering, Georgia Institute of Technology and Emory University 

 

Brandon Dixon, Ph.D. 

Department of Mechanical Engineering, Georgia Institute of Technology 

 

 

Next-generation lipid nanoparticle formulations for non-liver delivery of nucleic acid-based therapies and vaccines  

 

The clinical application of lipid nanoparticles (LNPs) delivering RNA therapies has advanced remarkably over the past few decades with the Food and Drug Administration (FDA) approval of ONPATTRO® in 2018 for treating liver genetic disease following systemic administration and the most recent COVID-19 vaccines developed by Moderna Therapeutics Inc. and Pfizer-BioNTech in 2021. Despite the success of first-generation LNP-RNA therapies, there still remains needs to rationally design next-generation LNP formulations for systemic non-liver delivery and for vaccination against other malignant diseases such as respiratory syncytial virus (RSV). In this work, we aimed to (i) identify helper lipid design rules and biological response for systemic lung mRNA delivery of LNPs, (ii) investigate the effect of cationic lipids in LNP formulation on systemic in vivo non-liver tropism, and (iii) develop a mRNA-based LNP vaccine for RSV. This work will establish the foundation towards two crucial objectives: (1) exploiting lipid nanoparticle design rules for systemic non-liver delivery of nucleic acid-based therapies (2) determining factors for LNP mRNA-based vaccine immunogenicity which will allow for taking a leap towards developing clinically relevant nucleic acid-based vaccines.  

Additional Information

In Campus Calendar
No
Groups

Bioengineering Graduate Program

Invited Audience
Faculty/Staff, Public, Undergraduate students
Categories
Career/Professional development
Keywords
go-BioE
Status
  • Created By: Laura Paige
  • Workflow Status: Published
  • Created On: Sep 14, 2022 - 11:45am
  • Last Updated: Sep 14, 2022 - 11:45am